Please login to the form below

Not currently logged in

Novo’s oral diabetes drug hits the mark again

Novo Nordisk headquarters

The drug proves effective in reducing blood sugar in diabetes patients with renal impairment

Armoured CAR ‘could overwhelm solid tumour resistance’

Eureka TherapeuticsEureka Therapeutics and Memorial Sloan Kettering approach shows promise

Regeneron and Teva close gap on rivals with NGF pain drug

regeneron headquartersFasinumab was associated with less pain and improved functional ability compared to placebo

Daily Brief: Summit's $12m lifeline, Biohaven's speech anxiety pill, Crescendo's Humabody progress

summit therapeuticsNews from pharma, biotech and healthcare

Daily Brief: another departure at Gilead, veteran researcher to head up Karuna

GileadExodus continues from Gilead

Realm toppled by second mid-stage trial flop

RealmThe hypochlorous acid gel failed to show EASI score improvement compared to placebo

DNA damage specialists Artios Pharma raises $84m

ArtiosTeam behind development of Lynparza focus on next-gen DDR inhibitors

Allergan builds on gene editing deal

Firm will co-develop CRISPR candidate for vision-threatening disorder

Regeneron and Bluebird sign $100m cell therapies deal

regeneron headquartersSix targets chosen from TCR and other cell therapy platforms

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Featured jobs

Subscribe to our email news alerts


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...